Méridian Strategic Advisors | Late-Stage Healthcare Capital
Méridian Strategic Advisors | Late-Stage Healthcare Capital
  • Home
  • How we work
  • Opportunities
  • Contact us
  • Privacy Policy
  • More
    • Home
    • How we work
    • Opportunities
    • Contact us
    • Privacy Policy
  • Home
  • How we work
  • Opportunities
  • Contact us
  • Privacy Policy

NEURO20 TECHNOLOGIES

FDA-Cleared Neuromodulation System for Neurological Rehabilitation

Neuro20 developed the first wearable whole-body electrical muscle stimulation system combining FDA-cleared medical-grade technology with proprietary Patterned Electrical Muscle Stimulation (PEMS). The system is currently treating patients at Johns Hopkins, Brooks Rehabilitation, Shepherd Center, and across the Encompass Health network.


TECHNOLOGY: Integrated smart suit delivers precise electrical stimulation replicating functional movement patterns. Therapist-controlled tablet interface enables customized protocols for individual patients. Clinical-grade durability with machine-washable design for repeated institutional use.


FDA CLEARANCE: 510(k) cleared for six indications: muscle strengthening, gait training, injury prevention, injury recovery, pre-surgery conditioning, post-surgery rehabilitation. GSA approved for VA hospital procurement.


CLINICAL DEPLOYMENT: Active treatment protocols at leading rehabilitation institutions demonstrate measurable improvements in strength, balance, and functional mobility for patients with spinal cord injury, stroke, MS, Parkinson's, and other neurological conditions.


LEADERSHIP: Dennis "DJ" Schmidt, Founder (former Marine, developed technology during personal recovery from neurological injury). Dr. Keith Cronin, CMO (rehabilitation medicine specialist).


COMMERCIAL TRAJECTORY:Encompass Health initiating trials across 170+ locations beginning January 2026. Technology validation complete, institutional partnerships established, patient outcomes documented.


MARKET REALITY: The $30+ billion neurological rehabilitation market currently lacks technologies bridging the gap between conventional therapy and meaningful functional recovery. Neuro20 addresses this directly with proven clinical outcomes.


FUNDING REQUIREMENT: $5 million for clinical trials establishing insurance reimbursement codes. This is the final regulatory checkpoint before widespread commercial deployment. The technology works, institutions are committed, outcomes are proven. Reimbursement codes unlock scale.


Videos: www.vimeo.com/neuro20

Back to Opportunities

  Méridian Strategic Advisors, Inc.

2020 Main Street, Suite 1225, Irvine, CA 92614

(310) 927-0159 ben@benlapointe.com

© 2026 Méridian Strategic Advisors. All rights reserved.